# Assumptions Matter: The Long-Term Cost Analysis of IsaVRd vs DVRd

**Authors:** Feng Lin, Audrey Petitjean, Medha Sasane

PMC · DOI: 10.36469/001c.145075 · Journal of Health Economics and Outcomes Research · 2025-10-17

## Full-text entities

- **Diseases:** toxicities (MESH:D064420), cancer (MESH:D009369), NDMM (MESH:D009101), organ dysfunction (MESH:D009102)
- **Chemicals:** Isatuximab (MESH:C000599209), HOPA (-), lenalidomide (MESH:D000077269), dexamethasone (MESH:D003907), daratumumab (MESH:C556306), bortezomib (MESH:D000069286)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12535738/full.md

## References

5 references — full list in the complete paper: https://tomesphere.com/paper/PMC12535738/full.md

---
Source: https://tomesphere.com/paper/PMC12535738